{"id":"NCT00046228","sponsor":"Centocor, Inc.","briefTitle":"A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)","officialTitle":"A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-08","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2002-09-25","resultsPosted":"2009-05-15","lastUpdate":"2014-07-31"},"enrollment":2461,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Myocardial Infarction"],"interventions":[{"type":"DRUG","name":"abciximab placebo; reteplase placebo, abciximab, abciximab","otherNames":[]},{"type":"DRUG","name":"Abciximab; reteplase; abciximab placebo; abciximab","otherNames":[]},{"type":"DRUG","name":"abciximab; reteplase placebo; abciximab placebo; abciximab","otherNames":[]},{"type":"DRUG","name":"abciximab placebo; reteplase placebo, abciximab, abciximab","otherNames":[]},{"type":"DRUG","name":"abciximab; reteplase placebo; abciximab placebo; abciximab","otherNames":[]},{"type":"DRUG","name":"Abciximab; reteplase; abciximab placebo; abciximab","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"EXPERIMENTAL"},{"label":"003","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.","primaryOutcome":{"measure":"The Composite of All-Cause Mortality or Complications of MI at 90 Days.","timeFrame":"90 days","effectByArm":[{"arm":"Primary PCI Group","deltaMin":86,"sd":null},{"arm":"Abciximab Facilitated PCI Group","deltaMin":86,"sd":null},{"arm":"Reteplase/Abciximab Facilitated PCI Group","deltaMin":81,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.551"},{"comp":"OG000 vs OG001","p":"0.858"},{"comp":"OG001 vs OG002","p":"0.676"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":227,"countries":["United States","Argentina","Austria","Belgium","Bulgaria","Canada","Czechia","Denmark","France","Germany","Israel","Netherlands","Poland","Romania","South Africa","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["15077099","18499565","20170878","19850249","19850248"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=15&filename=CR005410_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":159,"n":795},"commonTop":[]}}